The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 1.50 (8.824%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 17.75
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

3 Nov 2020 14:54

RNS Number : 1387E
Angle PLC
03 November 2020
 

ANGLE plc

("ANGLE" or "the Company")

 

Director/PDMR Dealings

 

 

ANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, has been notified that the following Directors of the Company purchased ordinary shares of 10 pence each in the Company ("Ordinary Shares") on 2 November 2020:

 

- Ian Griffiths, Finance Director of the Company, purchased 30,000 Ordinary Shares at a price of 44.75 pence per Ordinary Share. Following this purchase Mr. Griffiths is beneficially interested in a total of 703,832 Ordinary Shares, representing approximately 0.41 per cent of the Company's currently issued share capital; and

 

- Garth Selvey, Non-Executive Chairman of the Company, purchased 30,000 Ordinary Shares at a price of 45.00 pence per Ordinary Share. Following this purchase Mr. Selvey is beneficially interested in a total of 50,000 Ordinary Shares, representing approximately 0.03 per cent of the Company's currently issued share capital.

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

 

 

For further information ANGLE:

 

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance - Carl Holmes, Simon Hicks, Teddy Whiley

ECM - Alice Lane, Sunila de Silva

 

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

 

+44 (0) 203 705 9330

 

 

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

 

+44 (0) 203 727 1000

+1 212 850 5624

 

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

Name

 

 

Ian Griffiths

2

Reason for the notification

 

 

a)

Position/status

 

 

Finance Director

b) 

Initial notification /Amendment

 

 

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

Name

 

 

ANGLE plc

b)

LEI

 

 

213800BY11K6W3NMS374

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 10p each 

 

 

GB0034330679

b)

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

 

 Price(s) 

Volume(s)

44.75p 

30,000

d)

Aggregated information

- Aggregated volume

- Price

 

 

Purchase of 30,000 Ordinary Shares at 44.75p per Ordinary Share

e)

Date of the transaction

 

 

2 November 2020

f)

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

Name

 

 

Garth Selvey

2

Reason for the notification

 

 

a)

Position/status 

 

 

Non-Executive Chairman

b) 

Initial notification /Amendment 

 

 

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

Name 

 

 

ANGLE plc

b)

LEI

 

 

213800BY11K6W3NMS374

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 10p each 

 

 

GB0034330679

b)

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

 

 Price(s) 

Volume(s)

45.00p 

30,000

d)

Aggregated information

- Aggregated volume

- Price

 

 

Purchase of 30,000 Ordinary Shares at 45.00p per Ordinary Share

e)

Date of the transaction

 

 

2 November 2020

f)

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFBBFLEFBX
Date   Source Headline
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.